Therefore, we classified AML according to the combination of FLT3-ITD and NPM1 mutations and evaluated PPM1D expression across the subgroups (Kruskal Wallis test, GSE6891 p = 0.009). Here, FLT3 is linked to acute myeloid leukemia.